EUCTR2006-002477-45-CZ进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, multicenter evaluation of the efficacy and safety of terguride tablets, administered orally for 3 months, to patients with fibromyalgia.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients (m or f) are eligible for the study when they fulfil the following criteria:
- •·Diagnosis of fibromyalgia according to ACR criteria (1990) [Wolfe et al. 1990]
- •·Pain score ³50 mm on the patient pain VAS (100 mm)
- •·Tender point Score (TPS) ³ 11
- •·Age range from 18 to 60 y (inclusive)
- •·Body Mass Index (BMI): 18.9 < BMI < 30.0
- •·A written informed consent to participate in this study signed by the subject prior to initiation of any study specific procedure
- •·Treatment as outpatients
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A patient fulfilling the following exclusion criteria must not enter the study:
- •·known sensitivity to study drug
- •·suffering from relevant liver (limit for GOT and GPT: < 3-fold of upper limit of NR), kidney (limit for serum creatinine: < 1.5 mg/dL), cardiovascular (i.e. heart attack or cerebrovascular disease) or pulmonary disease (i.e. asthma or COPD)
- •·suffering from pituitary tumor representing extrasellar expansion
- •·suffering from peptic ulcers or having a history of it
- •·suffering from Raynaud syndrome or having a history of it
- •·suffering from psychosis or having a history of it
- •·suffering from a systolic blood pressure ³140 mm Hg and a diastolic pressure ³ 90 mm Hg. (Criteria in accordance with the 7th report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure (NIH Publication # 04-5230 (2004))
- •·suffering from Encephalomyelitis disseminata
- •·suffering from chronic inflammatory diseases
- •·evidence or history of drug or alcohol abuse
- •·mental impairment limiting the ability to comply with study requirements
- •·receiving therapy with agents known or likely to interact with study drug or disease:
- •- Antidepressants or SSRIs are not allowed from 6 weeks before V(-1) throughout the entire study. However, patients with substantial therapeutic benefit from such compounds should not be discontinued for study participation.
- •- Antiepileptics, Anxiolytics, Muscle relaxants or Hypnotics have to be discontinued at least 10 elimination half lives of the respective drug before V(-1); for details see section 9.4.7,
- •·participation in any clinical study or donation of blood in the period from 60 days prior to study initiation until end of study .
- •Additionally, women with child bearing potential must be excluded if:
- •·They have not used reliable contraception in the cycle before the study. According to CPMP/ICH/286/95 (modification) highly effective methods of birth control (defined by a failure rate < 1% per year) include the consistent and correct use of implants, injectables combined oral contraceptives, selected intrauterine devices (IUD), sexual abstinence or vasectomised partner The subject has to agree to continue using such highly reliable contraception during the entire study period and the cycle after the study
- •·They are pregnant or lactating. (A negative pregnancy test must be provided for all female subjects with child bearing potential at screening and on Day 0)
研究者
相似试验
已完成
2 期
A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19NL-OMON51156Molecular Partners AG200
招募中
4 期
Treatment of Verruca Plana by external application of tubeimoside injection: a randomized, double-blind, placebo-controlled, multicenter clinical trial.Flat WartITMCTR2000003368Shaanxi Provincial Hospital of Traditional Chinese Medicine
已完成
2 期
A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativaNL-OMON46646InflaRx GmbH4
尚未招募
1 期
Clinical evaluation for traditional Chinese medicine combined with antibiotics in the treatment of bacterial pneumonia in childreBacterial pneumonia in childrenITMCTR1900002538Affiliated Hospital of Changchun University of Traditional Chinese Medicine
招募中
1 期
A randomized, double-blind, placebo-controlled, multicenter clinical study on the efficacy and safety of hongjing-1 in the treatment of impotenceErectile DysfunctionITMCTR2100004505The Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine